Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy

Share :
Published: 12 Apr 2024
Views: 61
Rating:
Save
Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Dr Pasi Jänne speaks to ecancer about the FLAURA2 exploratory analysis of baseline and on-treatment plasma EGFRm dynamics in patients with EGFRm advanced NSCLC treated with first-line osimertinib and platinum-pemetrexed.

According to a recent study, patients with tumour cell DNA (ctDNA) that tested positive for an EGFR mutation before therapy could benefit significantly from osimertinib plus chemotherapy.

The study found that patients with EGFR-mutant ctDNA in their blood before therapy showed a higher degree of clinical benefit when treated with osimertinib and platinum-based chemotherapy, compared to those treated with osimertinib alone.

According to a recent study, patients with tumour cell DNA (ctDNA) that tested positive for an EGFR mutation before therapy could benefit significantly from osimertinib plus chemotherapy.

The study found that patients with EGFR-mutant ctDNA in their blood before therapy showed a higher degree of clinical benefit when treated with osimertinib and platinum-based chemotherapy, compared to those treated with osimertinib alone.

According to this study, patients with tumour cell DNA (ctDNA) that tested positive for an EGFR mutation before therapy could benefit significantly from osimertinib plus chemotherapy.

The study found that patients with EGFR-mutant ctDNA in their blood before therapy showed a higher degree of clinical benefit when treated with osimertinib and platinum-based chemotherapy, compared to those treated with osimertinib alone.